Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TBN in Healthy Subjects

NCT04667013 is registered in ClinicalTrials.gov with Guangzhou Magpie Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04667013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04667013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TBN in Healthy Subjects
Lead sponsor
Guangzhou Magpie Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2028
Completion date
August 30, 2029
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy